{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T03:00:56Z","timestamp":1789873256578,"version":"4.0.1"},"reference-count":251,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T00:00:00Z","timestamp":1789862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T00:00:00Z","timestamp":1789862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Postdoctoral Fellowship Program of CPSF","award":["BX20240428"],"award-info":[{"award-number":["BX20240428"]}]},{"name":"The Scientific Research Project of Hunan Provincial Health","award":["No. 20230957"],"award-info":[{"award-number":["No. 20230957"]}]},{"name":"Natural Science Foundation of Hunan Province","award":["No. 2025JJ60604"],"award-info":[{"award-number":["No. 2025JJ60604"]}]},{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"publisher","award":["2023ZD0506105"],"award-info":[{"award-number":["2023ZD0506105"]}],"id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Beijing Huakang Public Welfare Foundation","award":["EXZL-GX-040"],"award-info":[{"award-number":["EXZL-GX-040"]}]},{"name":"Beijing Kechuang Medical Development Foundation","award":["KC2023-JX-0186-RQ059"],"award-info":[{"award-number":["KC2023-JX-0186-RQ059"]}]},{"name":"Beijing Life Oasis Public Welfare Service Center","award":["BH004506"],"award-info":[{"award-number":["BH004506"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"DOI":"10.1186\/s12943-026-02786-4","type":"journal-article","created":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T02:01:55Z","timestamp":1789869715000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immune-pressure redistribution in resistance to PD-1\/PD-L1 blockade: mechanisms, biomarkers, and therapeutic design"],"prefix":"10.1186","volume":"25","author":[{"given":"Xiaodong","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alifujiang","family":"Hairulajiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ZhiHong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingwen","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeqian","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,20]]},"reference":[{"issue":"10066","key":"2786_CR1","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","volume":"389","author":"A Rittmeyer","year":"2017","unstructured":"Rittmeyer A, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255\u201365.","journal-title":"Lancet"},{"issue":"19","key":"2786_CR2","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015;373(19):1803\u201313.","journal-title":"N Engl J Med"},{"issue":"26","key":"2786_CR3","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015;372(26):2521\u201332.","journal-title":"N Engl J Med"},{"issue":"11","key":"2786_CR4","doi-asserted-by":"publisher","first-page":"e003743","DOI":"10.1136\/jitc-2021-003743","volume":"9","author":"MM Regan","year":"2021","unstructured":"Regan MM, et al. Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067. J Immunother Cancer. 2021;9(11):e003743.","journal-title":"J Immunother Cancer"},{"issue":"17","key":"2786_CR5","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1200\/JCO.2017.77.0412","volume":"36","author":"S Gettinger","year":"2018","unstructured":"Gettinger S, et al. Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non\u2013Small-Cell Lung Cancer: Results From the CA209-003 Study. J Clin Oncol. 2018;36(17):1675\u201384.","journal-title":"J Clin Oncol"},{"issue":"17","key":"2786_CR6","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non\u2013Small-Cell Lung Cancer. N Engl J Med. 2015;373(17):1627\u201339.","journal-title":"N Engl J Med"},{"issue":"15","key":"2786_CR7","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1200\/JCO.19.01464","volume":"38","author":"AB Warner","year":"2020","unstructured":"Warner AB, et al. Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade. J Clin Oncol. 2020;38(15):1655\u201363.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2786_CR8","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ccell.2023.12.013","volume":"42","author":"D Memon","year":"2024","unstructured":"Memon D, et al. Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer. Cancer Cell. 2024;42(2):209\u2013e2249.","journal-title":"Cancer Cell"},{"issue":"4","key":"2786_CR9","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma P, et al. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell. 2017;168(4):707\u201323.","journal-title":"Cell"},{"issue":"4","key":"2786_CR10","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ccell.2020.03.017","volume":"37","author":"AJ Schoenfeld","year":"2020","unstructured":"Schoenfeld AJ, Hellmann MD. Acquired Resistance to Immune Checkpoint Inhibitors. Cancer Cell. 2020;37(4):443\u201355.","journal-title":"Cancer Cell"},{"issue":"7528","key":"2786_CR11","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh PC, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568\u201371.","journal-title":"Nature"},{"issue":"127","key":"2786_CR12","doi-asserted-by":"publisher","first-page":"ra12737","DOI":"10.1126\/scitranslmed.3003689","volume":"4","author":"JM Taube","year":"2012","unstructured":"Taube JM, et al. Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape. Sci Transl Med. 2012;4(127):ra12737\u201312737.","journal-title":"Sci Transl Med"},{"issue":"5","key":"2786_CR13","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies M, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541\u201350.","journal-title":"Nat Med"},{"issue":"16, 2021","key":"2786_CR14","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","volume":"16","author":"S Bagchi","year":"2021","unstructured":"Bagchi S, Yuan R, Engleman EG. Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance. Annu Rev Pathol. 2021;16(16, 2021):223\u201349.","journal-title":"Annu Rev Pathol"},{"issue":"6","key":"2786_CR15","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/s41591-021-01331-8","volume":"27","author":"D Liu","year":"2021","unstructured":"Liu D, et al. Evolution of delayed resistance to immunotherapy in a melanoma responder. Nat Med. 2021;27(6):985\u201392.","journal-title":"Nat Med"},{"issue":"4","key":"2786_CR16","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","volume":"171","author":"N Riaz","year":"2017","unstructured":"Riaz N, et al. Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. Cell. 2017;171(4):934\u2013e94916.","journal-title":"Cell"},{"issue":"9","key":"2786_CR17","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1604958","volume":"375","author":"JM Zaretsky","year":"2016","unstructured":"Zaretsky JM, et al. Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. N Engl J Med. 2016;375(9):819\u201329.","journal-title":"N Engl J Med"},{"issue":"6","key":"2786_CR18","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","volume":"167","author":"JL Benci","year":"2016","unstructured":"Benci JL, et al. Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade. Cell. 2016;167(6):1540\u2013e155412.","journal-title":"Cell"},{"issue":"8","key":"2786_CR19","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers M, et al. IFN-\u03b3\u2013related mRNA profile predicts clinical response to PD-1 blockade. J Clin Investig. 2017;127(8):2930\u201340.","journal-title":"J Clin Investig"},{"issue":"7519","key":"2786_CR20","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nature13490","volume":"513","author":"OR Colegio","year":"2014","unstructured":"Colegio OR, et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature. 2014;513(7519):559\u201363.","journal-title":"Nature"},{"issue":"5","key":"2786_CR21","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.cmet.2016.08.011","volume":"24","author":"A Brand","year":"2016","unstructured":"Brand A, et al. LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells. Cell Metabol. 2016;24(5):657\u201371.","journal-title":"Cell Metabol"},{"issue":"7559","key":"2786_CR22","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nature14404","volume":"523","author":"S Spranger","year":"2015","unstructured":"Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity. Nature. 2015;523(7559):231\u20135.","journal-title":"Nature"},{"issue":"3","key":"2786_CR23","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","volume":"20","author":"BC Miller","year":"2019","unstructured":"Miller BC, et al. Subsets of exhausted CD8 + T cells differentially mediate tumor control and respond to checkpoint blockade. Nat Immunol. 2019;20(3):326\u201336.","journal-title":"Nat Immunol"},{"issue":"5","key":"2786_CR24","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.ccell.2020.09.001","volume":"38","author":"F Dammeijer","year":"2020","unstructured":"Dammeijer F, et al. The PD-1\/PD-L1-Checkpoint Restrains T\u00a0cell Immunity in Tumor-Draining Lymph Nodes. Cancer Cell. 2020;38(5):685\u2013e7008.","journal-title":"Cancer Cell"},{"issue":"7693","key":"2786_CR25","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan S, et al. TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554(7693):544\u20138.","journal-title":"Nature"},{"issue":"385","key":"2786_CR26","doi-asserted-by":"publisher","first-page":"eaak9679","DOI":"10.1126\/scitranslmed.aak9679","volume":"9","author":"E Allen","year":"2017","unstructured":"Allen E, et al. Combined antiangiogenic and anti\u2013PD-L1 therapy stimulates tumor immunity through HEV formation. Sci Transl Med. 2017;9(385):eaak9679.","journal-title":"Sci Transl Med"},{"issue":"7385","key":"2786_CR27","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/nature10755","volume":"482","author":"H Matsushita","year":"2012","unstructured":"Matsushita H, et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature. 2012;482(7385):400\u20134.","journal-title":"Nature"},{"issue":"7171","key":"2786_CR28","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1038\/nature06309","volume":"450","author":"CM Koebel","year":"2007","unstructured":"Koebel CM, et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature. 2007;450(7171):903\u20137.","journal-title":"Nature"},{"issue":"6024","key":"2786_CR29","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1126\/science.1203486","volume":"331","author":"RD Schreiber","year":"2011","unstructured":"Schreiber RD, Old LJ, Smyth MJ. Cancer Immunoediting: Integrating Immunity\u2019s Roles in Cancer Suppression and Promotion. Science. 2011;331(6024):1565\u201370.","journal-title":"Science"},{"issue":"7","key":"2786_CR30","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","volume":"8","author":"F Skoulidis","year":"2018","unstructured":"Skoulidis F, et al. STK11\/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. Cancer Discov. 2018;8(7):822\u201335.","journal-title":"Cancer Discov"},{"issue":"4","key":"2786_CR31","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","volume":"175","author":"M Sade-Feldman","year":"2018","unstructured":"Sade-Feldman M, et al. Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. Cell. 2018;175(4):998\u2013e101320.","journal-title":"Cell"},{"issue":"7681","key":"2786_CR32","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nature24473","volume":"551","author":"M \u0141uksza","year":"2017","unstructured":"\u0141uksza M, et al. A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy. Nature. 2017;551(7681):517\u201320.","journal-title":"Nature"},{"issue":"6280","key":"2786_CR33","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1126\/science.aaf1490","volume":"351","author":"N McGranahan","year":"2016","unstructured":"McGranahan N, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016;351(6280):1463\u20139.","journal-title":"Science"},{"issue":"6375","key":"2786_CR34","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1126\/science.aao4572","volume":"359","author":"D Chowell","year":"2018","unstructured":"Chowell D, et al. Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science. 2018;359(6375):582\u20137.","journal-title":"Science"},{"issue":"4","key":"2786_CR35","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.cell.2018.09.006","volume":"175","author":"L Jerby-Arnon","year":"2018","unstructured":"Jerby-Arnon L, et al. A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. Cell. 2018;175(4):984\u2013e99724.","journal-title":"Cell"},{"issue":"7693","key":"2786_CR36","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/nature25492","volume":"554","author":"DVF Tauriello","year":"2018","unstructured":"Tauriello DVF, et al. TGF\u03b2 drives immune evasion in genetically reconstituted colon cancer metastasis. Nature. 2018;554(7693):538\u201343.","journal-title":"Nature"},{"issue":"7629","key":"2786_CR37","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/nature20554","volume":"539","author":"O De Henau","year":"2016","unstructured":"De Henau O, et al. Overcoming resistance to checkpoint blockade therapy by targeting PI3K\u03b3 in myeloid cells. Nature. 2016;539(7629):443\u20137.","journal-title":"Nature"},{"issue":"1","key":"2786_CR38","doi-asserted-by":"publisher","first-page":"10501","DOI":"10.1038\/ncomms10501","volume":"7","author":"S Koyama","year":"2016","unstructured":"Koyama S, et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun. 2016;7(1):10501.","journal-title":"Nat Commun"},{"issue":"3","key":"2786_CR39","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/s41591-019-0357-y","volume":"25","author":"AC Huang","year":"2019","unstructured":"Huang AC, et al. A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nat Med. 2019;25(3):454\u201361.","journal-title":"Nat Med"},{"issue":"8","key":"2786_CR40","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1158\/2159-8290.CD-15-1545","volume":"6","author":"P-L Chen","year":"2016","unstructured":"Chen P-L, et al. Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discov. 2016;6(8):827\u201337.","journal-title":"Cancer Discov"},{"issue":"7652","key":"2786_CR41","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/nature22079","volume":"545","author":"AC Huang","year":"2017","unstructured":"Huang AC, et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature. 2017;545(7652):60\u20135.","journal-title":"Nature"},{"issue":"3","key":"2786_CR42","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1158\/2159-8290.CD-16-0828","volume":"7","author":"V Anagnostou","year":"2017","unstructured":"Anagnostou V, et al. Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non\u2013Small Cell Lung Cancer. Cancer Discov. 2017;7(3):264\u201376.","journal-title":"Cancer Discov"},{"issue":"36","key":"2786_CR43","doi-asserted-by":"publisher","first-page":"3546","DOI":"10.1200\/JCO.19.00709","volume":"37","author":"JC Osorio","year":"2019","unstructured":"Osorio JC, et al. Lesion-Level Response Dynamics to Programmed Cell Death Protein (PD-1) Blockade. J Clin Oncol. 2019;37(36):3546\u201355.","journal-title":"J Clin Oncol"},{"issue":"5","key":"2786_CR44","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.cell.2017.07.025","volume":"170","author":"A Jim\u00e9nez-S\u00e1nchez","year":"2017","unstructured":"Jim\u00e9nez-S\u00e1nchez A, et al. Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient. Cell. 2017;170(5):927\u2013e93820.","journal-title":"Cell"},{"issue":"8","key":"2786_CR45","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1158\/1078-0432.CCR-19-2226","volume":"26","author":"I Matos","year":"2020","unstructured":"Matos I, et al. Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria. Clin Cancer Res. 2020;26(8):1846\u201355.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2786_CR46","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1001\/jamaoncol.2018.3676","volume":"4","author":"R Ferrara","year":"2018","unstructured":"Ferrara R, et al. Hyperprogressive Disease in Patients With Advanced Non\u2013Small Cell Lung Cancer Treated With PD-1\/PD-L1 Inhibitors or With Single-Agent Chemotherapy. JAMA Oncol. 2018;4(11):1543\u201352.","journal-title":"JAMA Oncol"},{"issue":"8","key":"2786_CR47","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1158\/1078-0432.CCR-16-1741","volume":"23","author":"S Champiat","year":"2017","unstructured":"Champiat S, et al. Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1\/PD-L1. Clin Cancer Res. 2017;23(8):1920\u20138.","journal-title":"Clin Cancer Res"},{"issue":"15","key":"2786_CR48","doi-asserted-by":"publisher","first-page":"4242","DOI":"10.1158\/1078-0432.CCR-16-3133","volume":"23","author":"S Kato","year":"2017","unstructured":"Kato S, et al. Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate. Clin Cancer Res. 2017;23(15):4242\u201350.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2786_CR49","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1158\/1078-0432.CCR-18-1390","volume":"25","author":"G Lo Russo","year":"2019","unstructured":"Lo Russo G, et al. Antibody\u2013Fc\/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non\u2013small Cell Lung Cancer Subsequent to PD-1\/PD-L1 Blockade. Clin Cancer Res. 2019;25(3):989\u201399.","journal-title":"Clin Cancer Res"},{"issue":"6832","key":"2786_CR50","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1038\/35074122","volume":"410","author":"V Shankaran","year":"2001","unstructured":"Shankaran V, et al. IFN\u03b3 and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001;410(6832):1107\u201311.","journal-title":"Nature"},{"issue":"7","key":"2786_CR51","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1038\/s41591-020-0892-6","volume":"26","author":"BM Allen","year":"2020","unstructured":"Allen BM, et al. Systemic dysfunction and plasticity of the immune macroenvironment in cancer models. Nat Med. 2020;26(7):1125\u201334.","journal-title":"Nat Med"},{"issue":"6","key":"2786_CR52","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.cell.2017.10.001","volume":"171","author":"N McGranahan","year":"2017","unstructured":"McGranahan N, et al. Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. Cell. 2017;171(6):1259\u2013e127111.","journal-title":"Cell"},{"issue":"12","key":"2786_CR53","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1158\/2159-8290.CD-17-0593","volume":"7","author":"S Gettinger","year":"2017","unstructured":"Gettinger S, et al. Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. Cancer Discov. 2017;7(12):1420\u201335.","journal-title":"Cancer Discov"},{"issue":"1","key":"2786_CR54","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","volume":"386","author":"HA Tawbi","year":"2022","unstructured":"Tawbi HA, et al. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. N Engl J Med. 2022;386(1):24\u201334.","journal-title":"N Engl J Med"},{"issue":"10","key":"2786_CR55","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1084\/jem.20101158","volume":"208","author":"MS Diamond","year":"2011","unstructured":"Diamond MS, et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med. 2011;208(10):1989\u20132003.","journal-title":"J Exp Med"},{"issue":"4","key":"2786_CR56","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1158\/0008-5472.CAN-15-3142","volume":"77","author":"X Wang","year":"2017","unstructured":"Wang X, et al. Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy. Cancer Res. 2017;77(4):839\u201350.","journal-title":"Cancer Res"},{"issue":"1","key":"2786_CR57","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s43018-022-00490-y","volume":"4","author":"J Qiu","year":"2023","unstructured":"Qiu J, et al. Cancer cells resistant to immune checkpoint blockade acquire interferon-associated epigenetic memory to sustain T cell dysfunction. Nat Cancer. 2023;4(1):43\u201361.","journal-title":"Nat Cancer"},{"issue":"6","key":"2786_CR58","doi-asserted-by":"publisher","first-page":"eaai8593","DOI":"10.1126\/sciimmunol.aai8593","volume":"1","author":"T Wu","year":"2016","unstructured":"Wu T, et al. The TCF1-Bcl6 axis counteracts type I interferon to repress exhaustion and maintain T cell stemness. Sci Immunol. 2016;1(6):eaai8593.","journal-title":"Sci Immunol"},{"issue":"6","key":"2786_CR59","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.cell.2015.08.012","volume":"162","author":"P-C Ho","year":"2015","unstructured":"Ho P-C, et al. Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses. Cell. 2015;162(6):1217\u201328.","journal-title":"Cell"},{"issue":"7851","key":"2786_CR60","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/s41586-020-03045-2","volume":"591","author":"MJ Watson","year":"2021","unstructured":"Watson MJ, et al. Metabolic support of tumour-infiltrating regulatory T cells by lactic acid. Nature. 2021;591(7851):645\u201351.","journal-title":"Nature"},{"issue":"6055","key":"2786_CR61","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/319675a0","volume":"319","author":"K K\u00e4rre","year":"1986","unstructured":"K\u00e4rre K, et al. Selective rejection of H\u20132-deficient lymphoma variants suggests alternative immune defence strategy. Nature. 1986;319(6055):675\u20138.","journal-title":"Nature"},{"issue":"6","key":"2786_CR62","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.ccr.2011.11.006","volume":"20","author":"M Challa-Malladi","year":"2011","unstructured":"Challa-Malladi M, et al. Combined Genetic Inactivation of <\u2009em>\u03b22-Microglobulin\u2009and CD58 Reveals Frequent Escape from Immune Recognition in Diffuse Large B Cell Lymphoma. Cancer Cell. 2011;20(6):728\u201340.","journal-title":"Cancer Cell"},{"issue":"6669","key":"2786_CR63","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/35869","volume":"391","author":"VM Braud","year":"1998","unstructured":"Braud VM, et al. HLA-E binds to natural killer cell receptors CD94\/NKG2A, B and. Nature. 1998;391(6669):795\u20139.","journal-title":"Nature"},{"issue":"10","key":"2786_CR64","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1038\/s41590-022-01315-x","volume":"23","author":"J Dubrot","year":"2022","unstructured":"Dubrot J, et al. In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer. Nat Immunol. 2022;23(10):1495\u2013506.","journal-title":"Nat Immunol"},{"issue":"21","key":"2786_CR65","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","volume":"372","author":"EB Garon","year":"2015","unstructured":"Garon EB, et al. Pembrolizumab for the Treatment of Non\u2013Small-Cell Lung Cancer. N Engl J Med. 2015;372(21):2018\u201328.","journal-title":"N Engl J Med"},{"issue":"26","key":"2786_CR66","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le DT, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509\u201320.","journal-title":"N Engl J Med"},{"issue":"6230","key":"2786_CR67","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi NA, et al. Mutational landscape determines sensitivity to PD-1 blockade in non\u2013small cell lung cancer. Science. 2015;348(6230):124\u20138.","journal-title":"Science"},{"issue":"7791","key":"2786_CR68","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","volume":"577","author":"BA Helmink","year":"2020","unstructured":"Helmink BA, et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020;577(7791):549\u201355.","journal-title":"Nature"},{"issue":"6","key":"2786_CR69","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.immuni.2018.09.024","volume":"49","author":"CS Garris","year":"2018","unstructured":"Garris CS, et al. Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-\u03b3 and IL-12. Immunity. 2018;49(6):1148\u2013e11617.","journal-title":"Immunity"},{"issue":"2","key":"2786_CR70","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1158\/2159-8290.CD-15-0283","volume":"6","author":"W Peng","year":"2016","unstructured":"Peng W, et al. Loss of PTEN Promotes Resistance to T Cell\u2013Mediated Immunotherapy. Cancer Discov. 2016;6(2):202\u201316.","journal-title":"Cancer Discov"},{"issue":"18","key":"2786_CR71","doi-asserted-by":"publisher","first-page":"4585","DOI":"10.1158\/1078-0432.CCR-15-3101","volume":"22","author":"JF Gainor","year":"2016","unstructured":"Gainor JF, et al. Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non\u2013Small Cell Lung Cancer: A Retrospective Analysis. Clin Cancer Res. 2016;22(18):4585\u201393.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2786_CR72","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/j.jtho.2018.03.035","volume":"13","author":"A Lisberg","year":"2018","unstructured":"Lisberg A, et al. A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Na\u00efve Patients With Advanced NSCLC. J Thorac Oncol. 2018;13(8):1138\u201345.","journal-title":"J Thorac Oncol"},{"issue":"5","key":"2786_CR73","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/j.cell.2020.07.005","volume":"182","author":"CM Sch\u00fcrch","year":"2020","unstructured":"Sch\u00fcrch CM, et al. Coordinated Cellular Neighborhoods Orchestrate Antitumoral Immunity at the Colorectal Cancer Invasive Front. Cell. 2020;182(5):1341\u2013e135919.","journal-title":"Cell"},{"issue":"6","key":"2786_CR74","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/j.cell.2018.08.039","volume":"174","author":"L Keren","year":"2018","unstructured":"Keren L, et al. A Structured Tumor-Immune Microenvironment in Triple Negative Breast Cancer Revealed by Multiplexed Ion Beam Imaging. Cell. 2018;174(6):1373\u2013e138719.","journal-title":"Cell"},{"issue":"7787","key":"2786_CR75","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41586-019-1836-5","volume":"576","author":"CS Jansen","year":"2019","unstructured":"Jansen CS, et al. An intra-tumoral niche maintains and differentiates stem-like CD8 T cells. Nature. 2019;576(7787):465\u201370.","journal-title":"Nature"},{"issue":"64","key":"2786_CR76","doi-asserted-by":"publisher","first-page":"eabg7836","DOI":"10.1126\/sciimmunol.abg7836","volume":"6","author":"KA Connolly","year":"2021","unstructured":"Connolly KA, et al. A reservoir of stem-like CD8 < sup>+ T cells in the tumor-draining lymph node preserves the ongoing antitumor immune response. Sci Immunol. 2021;6(64):eabg7836.","journal-title":"Sci Immunol"},{"issue":"22","key":"2786_CR77","doi-asserted-by":"publisher","first-page":"4049","DOI":"10.1016\/j.cell.2022.09.020","volume":"185","author":"Q Huang","year":"2022","unstructured":"Huang Q, et al. The primordial differentiation of tumor-specific memory CD8\u2009<\u2009sup>+\u2009T\u00a0cells as bona fide responders to PD-1\/PD-L1 blockade in draining lymph nodes. Cell. 2022;185(22):4049\u2013e406625.","journal-title":"Cell"},{"issue":"5","key":"2786_CR78","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/s41591-020-0856-x","volume":"26","author":"KA Schalper","year":"2020","unstructured":"Schalper KA, et al. Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors. Nat Med. 2020;26(5):688\u201392.","journal-title":"Nat Med"},{"issue":"10","key":"2786_CR79","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1001\/jamaoncol.2019.1747","volume":"5","author":"D Kazandjian","year":"2019","unstructured":"Kazandjian D, et al. Prognostic Value of the Lung Immune Prognostic Index for Patients Treated for Metastatic Non\u2013Small Cell Lung Cancer. JAMA Oncol. 2019;5(10):1481\u20135.","journal-title":"JAMA Oncol"},{"issue":"8","key":"2786_CR80","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1158\/1078-0432.CCR-17-1341","volume":"24","author":"SB Goldberg","year":"2018","unstructured":"Goldberg SB, et al. Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA. Clin Cancer Res. 2018;24(8):1872\u201380.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2786_CR81","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1158\/0008-5472.CAN-18-1127","volume":"79","author":"V Anagnostou","year":"2019","unstructured":"Anagnostou V, et al. Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non\u2013Small Cell Lung Cancer. Cancer Res. 2019;79(6):1214\u201325.","journal-title":"Cancer Res"},{"issue":"9","key":"2786_CR82","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1038\/s43018-020-0096-5","volume":"1","author":"SV Bratman","year":"2020","unstructured":"Bratman SV, et al. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. Nat Cancer. 2020;1(9):873\u201381.","journal-title":"Nat Cancer"},{"issue":"19","key":"2786_CR83","doi-asserted-by":"publisher","first-page":"4993","DOI":"10.1073\/pnas.1705327114","volume":"114","author":"AO Kamphorst","year":"2017","unstructured":"Kamphorst AO, et al. Proliferation of PD-1\u2009+\u2009CD8 T cells in peripheral blood after PD-1\u2013targeted therapy in lung cancer patients. Proc Natl Acad Sci. 2017;114(19):4993\u20138.","journal-title":"Proc Natl Acad Sci"},{"issue":"3","key":"2786_CR84","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/s41591-022-01695-5","volume":"28","author":"KA Lee","year":"2022","unstructured":"Lee KA, et al. Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma. Nat Med. 2022;28(3):535\u201344.","journal-title":"Nat Med"},{"issue":"7","key":"2786_CR85","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1158\/2159-8290.CD-20-0987","volume":"11","author":"G Germano","year":"2021","unstructured":"Germano G, et al. CD4 T Cell\u2013Dependent Rejection of Beta-2 Microglobulin Null Mismatch Repair\u2013Deficient Tumors. Cancer Discov. 2021;11(7):1844\u201359.","journal-title":"Cancer Discov"},{"issue":"7934","key":"2786_CR86","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41586-022-05368-8","volume":"611","author":"RN Amaria","year":"2022","unstructured":"Amaria RN, et al. Neoadjuvant relatlimab and nivolumab in resectable melanoma. Nature. 2022;611(7934):155\u201360.","journal-title":"Nature"},{"issue":"12","key":"2786_CR87","doi-asserted-by":"publisher","first-page":"4301","DOI":"10.1038\/s41591-025-04032-8","volume":"31","author":"GV Long","year":"2025","unstructured":"Long GV, et al. Adjuvant nivolumab and relatlimab in stage III\/IV melanoma: the randomized phase 3 RELATIVITY-098 trial. Nat Med. 2025;31(12):4301\u20139.","journal-title":"Nat Med"},{"issue":"1","key":"2786_CR88","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.immuni.2018.12.021","volume":"50","author":"I Siddiqui","year":"2019","unstructured":"Siddiqui I, et al. Intratumoral Tcf1 < sup>+ PD-1 < sup>+CD8 < sup>+ T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy. Immunity. 2019;50(1):195\u2013e21110.","journal-title":"Immunity"},{"issue":"8048","key":"2786_CR89","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1038\/s41586-024-08290-3","volume":"637","author":"A Lyu","year":"2025","unstructured":"Lyu A, et al. Evolution of myeloid-mediated immunotherapy resistance in prostate cancer. Nature. 2025;637(8048):1207\u201317.","journal-title":"Nature"},{"issue":"1","key":"2786_CR90","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1158\/2159-8290.CD-19-0980","volume":"10","author":"L Fong","year":"2020","unstructured":"Fong L, et al. Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer. Cancer Discov. 2020;10(1):40\u201353.","journal-title":"Cancer Discov"},{"issue":"5","key":"2786_CR91","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1158\/2326-6066.CIR-14-0211","volume":"3","author":"PA Beavis","year":"2015","unstructured":"Beavis PA, et al. Adenosine Receptor 2A Blockade Increases the Efficacy of Anti\u2013PD-1 through Enhanced Antitumor T-cell Responses. Cancer Immunol Res. 2015;3(5):506\u201317.","journal-title":"Cancer Immunol Res"},{"issue":"6702","key":"2786_CR92","doi-asserted-by":"publisher","first-page":"eadf1329","DOI":"10.1126\/science.adf1329","volume":"384","author":"D Mathew","year":"2024","unstructured":"Mathew D, et al. Combined JAK inhibition and PD-1 immunotherapy for non\u2013small cell lung cancer patients. Science. 2024;384(6702):eadf1329.","journal-title":"Science"},{"issue":"6702","key":"2786_CR93","doi-asserted-by":"publisher","first-page":"eade8520","DOI":"10.1126\/science.ade8520","volume":"384","author":"J Zak","year":"2024","unstructured":"Zak J, et al. JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma. Science. 2024;384(6702):eade8520.","journal-title":"Science"},{"key":"2786_CR94","doi-asserted-by":"publisher","first-page":"115547","DOI":"10.1016\/j.ejca.2025.115547","volume":"225","author":"EJ Lipson","year":"2025","unstructured":"Lipson EJ, et al. Nivolumab plus relatlimab in advanced melanoma: RELATIVITY-047 4-year update. Eur J Cancer. 2025;225:115547.","journal-title":"Eur J Cancer"},{"issue":"1","key":"2786_CR95","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa2407417","volume":"392","author":"JD Wolchok","year":"2025","unstructured":"Wolchok JD, et al. Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma. N Engl J Med. 2025;392(1):11\u201322.","journal-title":"N Engl J Med"},{"issue":"3","key":"2786_CR96","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/S1470-2045(25)00709-0","volume":"27","author":"R Dummer","year":"2026","unstructured":"Dummer R, et al. Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB\u2013IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 study. Lancet Oncol. 2026;27(3):327\u201339.","journal-title":"Lancet Oncol"},{"issue":"8","key":"2786_CR97","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/S1470-2045(19)30274-8","volume":"20","author":"GV Long","year":"2019","unstructured":"Long GV, et al. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): a phase 3, randomised, double-blind study. Lancet Oncol. 2019;20(8):1083\u201397.","journal-title":"Lancet Oncol"},{"issue":"29","key":"2786_CR98","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1200\/JCO.22.00227","volume":"40","author":"RS Herbst","year":"2022","unstructured":"Herbst RS, et al. An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer. J Clin Oncol. 2022;40(29):3383\u201393.","journal-title":"J Clin Oncol"},{"issue":"10","key":"2786_CR99","doi-asserted-by":"publisher","first-page":"3475","DOI":"10.1038\/s41591-025-03867-5","volume":"31","author":"BI Rini","year":"2025","unstructured":"Rini BI, et al. Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial. Nat Med. 2025;31(10):3475\u201384.","journal-title":"Nat Med"},{"issue":"6","key":"2786_CR100","first-page":"655","volume":"13","author":"RS Finn","year":"2024","unstructured":"Finn RS, et al. Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma with Main Trunk and\/or Contralateral Portal Vein Invasion in IMbrave150. Liver Cancer. 2024;13(6):655\u201368.","journal-title":"Liver Cancer"},{"issue":"12","key":"2786_CR101","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.jtho.2023.08.018","volume":"18","author":"BC Cho","year":"2023","unstructured":"Cho BC, et al. Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1-High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial. J Thorac Oncol. 2023;18(12):1731\u201342.","journal-title":"J Thorac Oncol"},{"issue":"6529","key":"2786_CR102","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1126\/science.abf3363","volume":"371","author":"D Davar","year":"2021","unstructured":"Davar D, et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science. 2021;371(6529):595\u2013602.","journal-title":"Science"},{"issue":"1","key":"2786_CR103","doi-asserted-by":"publisher","first-page":"4958","DOI":"10.1038\/s41467-025-60281-8","volume":"16","author":"M Emmers","year":"2025","unstructured":"Emmers M, et al. TEIPP-vaccination in checkpoint-resistant non-small cell lung cancer: a first-in-human phase I\/II dose-escalation study. Nat Commun. 2025;16(1):4958.","journal-title":"Nat Commun"},{"issue":"33","key":"2786_CR104","doi-asserted-by":"publisher","first-page":"3565","DOI":"10.1200\/JCO-25-00765","volume":"43","author":"T Medina","year":"2025","unstructured":"Medina T, et al. Long-Term Efficacy and Safety of Lifileucel Tumor-Infiltrating Lymphocyte Cell Therapy in Patients With Advanced Melanoma: A 5-Year Analysis of the C-144-01 Study. J Clin Oncol. 2025;43(33):3565\u201372.","journal-title":"J Clin Oncol"},{"issue":"21","key":"2786_CR105","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1200\/JCO.21.00174","volume":"39","author":"M Reck","year":"2021","unstructured":"Reck M, et al. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score \u2265 50. J Clin Oncol. 2021;39(21):2339\u201349.","journal-title":"J Clin Oncol"},{"issue":"10","key":"2786_CR106","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","volume":"21","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21(10):1353\u201365.","journal-title":"Lancet Oncol"},{"issue":"2","key":"2786_CR107","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","volume":"51","author":"RM Samstein","year":"2019","unstructured":"Samstein RM, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019;51(2):202\u20136.","journal-title":"Nat Genet"},{"issue":"1","key":"2786_CR108","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1038\/s41467-017-01062-w","volume":"8","author":"M Sade-Feldman","year":"2017","unstructured":"Sade-Feldman M, et al. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat Commun. 2017;8(1):1136.","journal-title":"Nat Commun"},{"issue":"8","key":"2786_CR109","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers M, et al. IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017;127(8):2930\u201340.","journal-title":"J Clin Invest"},{"key":"2786_CR110","doi-asserted-by":"crossref","unstructured":"Gu\u00e9gan J-P et al. Analysis of PD1, LAG3, TIGIT, and TIM3 expression in human lung adenocarcinoma reveals a 25-gene signature predicting immunotherapy response. Cell Rep Med, 2024; 5(12).","DOI":"10.1016\/j.xcrm.2024.101831"},{"issue":"699","key":"2786_CR111","doi-asserted-by":"publisher","first-page":"eadh8005","DOI":"10.1126\/scitranslmed.adh8005","volume":"15","author":"BH Herzog","year":"2023","unstructured":"Herzog BH, et al. Tumor-associated fibrosis impairs immune surveillance and response to immune checkpoint blockade in non-small cell lung cancer. Sci Transl Med. 2023;15(699):eadh8005.","journal-title":"Sci Transl Med"},{"issue":"5","key":"2786_CR112","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.ccell.2020.09.001","volume":"38","author":"F Dammeijer","year":"2020","unstructured":"Dammeijer F, et al. The PD-1\/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes. Cancer Cell. 2020;38(5):685\u2013e7008.","journal-title":"Cancer Cell"},{"issue":"1","key":"2786_CR113","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/s41467-021-20935-9","volume":"12","author":"C Valero","year":"2021","unstructured":"Valero C, et al. Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors. Nat Commun. 2021;12(1):729.","journal-title":"Nat Commun"},{"issue":"10","key":"2786_CR114","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1038\/s41591-023-02598-9","volume":"29","author":"V Anagnostou","year":"2023","unstructured":"Anagnostou V, et al. ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results. Nat Med. 2023;29(10):2559\u201369.","journal-title":"Nat Med"},{"issue":"2","key":"2786_CR115","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1158\/1078-0432.CCR-23-1469","volume":"30","author":"JC Murray","year":"2024","unstructured":"Murray JC, et al. Elucidating the Heterogeneity of Immunotherapy Response and Immune-Related Toxicities by Longitudinal ctDNA and Immune Cell Compartment Tracking in Lung Cancer. Clin Cancer Res. 2024;30(2):389\u2013403.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2786_CR116","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1158\/2159-8290.CD-15-0283","volume":"6","author":"W Peng","year":"2016","unstructured":"Peng W, et al. Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov. 2016;6(2):202\u201316.","journal-title":"Cancer Discov"},{"issue":"8038","key":"2786_CR117","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/s41586-024-07943-7","volume":"635","author":"F Skoulidis","year":"2024","unstructured":"Skoulidis F, et al. CTLA4 blockade abrogates KEAP1\/STK11-related resistance to PD-(L)1 inhibitors. Nature. 2024;635(8038):462\u201371.","journal-title":"Nature"},{"issue":"6371","key":"2786_CR118","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","volume":"359","author":"V Gopalakrishnan","year":"2018","unstructured":"Gopalakrishnan V, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018;359(6371):97\u2013103.","journal-title":"Science"},{"issue":"21","key":"2786_CR119","doi-asserted-by":"publisher","first-page":"5347","DOI":"10.1158\/1078-0432.CCR-18-1116","volume":"24","author":"CH Kugel III","year":"2018","unstructured":"Kugel CH III, et al. Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations. Clin Cancer Res. 2018;24(21):5347\u201356.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2786_CR120","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1016\/S1470-2045(21)00546-5","volume":"22","author":"DC Qian","year":"2021","unstructured":"Qian DC, et al. Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study. Lancet Oncol. 2021;22(12):1777\u201386.","journal-title":"Lancet Oncol"},{"issue":"7620","key":"2786_CR121","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nature19330","volume":"537","author":"SJ Im","year":"2016","unstructured":"Im SJ, et al. Defining CD8 + T cells that provide the proliferative burst after PD-1 therapy. Nature. 2016;537(7620):417\u201321.","journal-title":"Nature"},{"issue":"5","key":"2786_CR122","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.immuni.2020.04.014","volume":"52","author":"J-C Beltra","year":"2020","unstructured":"Beltra J-C, et al. Developmental Relationships of Four Exhausted CD8 < sup>+ T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms. Immunity. 2020;52(5):825\u2013e8418.","journal-title":"Immunity"},{"issue":"7764","key":"2786_CR123","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41586-019-1325-x","volume":"571","author":"O Khan","year":"2019","unstructured":"Khan O, et al. TOX transcriptionally and epigenetically programs CD8 + T cell exhaustion. Nature. 2019;571(7764):211\u20138.","journal-title":"Nature"},{"issue":"4","key":"2786_CR124","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1158\/0008-5472.CAN-11-1620","volume":"72","author":"S-R Woo","year":"2012","unstructured":"Woo S-R, et al. Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape. Cancer Res. 2012;72(4):917\u201327.","journal-title":"Cancer Res"},{"issue":"16","key":"2786_CR125","doi-asserted-by":"publisher","first-page":"4373","DOI":"10.1016\/j.cell.2024.06.036","volume":"187","author":"AR Cillo","year":"2024","unstructured":"Cillo AR, et al. Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8 < sup>+ T cells to promote antitumor immunity. Cell. 2024;187(16):4373\u2013e438815.","journal-title":"Cell"},{"issue":"9","key":"2786_CR126","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1084\/jem.20130579","volume":"210","author":"TR Simpson","year":"2013","unstructured":"Simpson TR, et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti\u2013CTLA-4 therapy against melanoma. J Exp Med. 2013;210(9):1695\u2013710.","journal-title":"J Exp Med"},{"issue":"4","key":"2786_CR127","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1158\/1078-0432.CCR-18-0762","volume":"25","author":"A Sharma","year":"2019","unstructured":"Sharma A, et al. Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3 + Regulatory T Cells (Tregs) in Human Cancers. Clin Cancer Res. 2019;25(4):1233\u20138.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2786_CR128","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015;373(1):23\u201334.","journal-title":"N Engl J Med"},{"issue":"8","key":"2786_CR129","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, et al. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. N Engl J Med. 2010;363(8):711\u201323.","journal-title":"N Engl J Med"},{"issue":"6","key":"2786_CR130","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1001\/jamaoncol.2026.0818","volume":"12","author":"MA Socinski","year":"2026","unstructured":"Socinski MA, et al. Tiragolumab Plus Atezolizumab and Chemotherapy for Advanced Nonsquamous Non\u2013Small Cell Lung Cancer: The Phase 3 SKYSCRAPER-06 Randomized Clinical Trial. JAMA Oncol. 2026;12(6):619\u201327.","journal-title":"JAMA Oncol"},{"issue":"6","key":"2786_CR131","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S1470-2045(22)00226-1","volume":"23","author":"BC Cho","year":"2022","unstructured":"Cho BC, et al. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study. Lancet Oncol. 2022;23(6):781\u201392.","journal-title":"Lancet Oncol"},{"issue":"1","key":"2786_CR132","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S1470-2045(25)00401-2","volume":"27","author":"C-H Hsu","year":"2026","unstructured":"Hsu C-H, et al. Tiragolumab plus atezolizumab and chemotherapy as first-line treatment for patients with unresectable oesophageal squamous cell carcinoma (SKYSCRAPER-08): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2026;27(1):103\u201315.","journal-title":"Lancet Oncol"},{"issue":"6","key":"2786_CR133","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.ccell.2014.10.018","volume":"26","author":"RJ Johnston","year":"2014","unstructured":"Johnston RJ, et al. The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 < sup>+ T Cell Effector Function. Cancer Cell. 2014;26(6):923\u201337.","journal-title":"Cancer Cell"},{"issue":"5","key":"2786_CR134","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1172\/JCI80445","volume":"125","author":"J-M Chauvin","year":"2015","unstructured":"Chauvin J-M, et al. TIGIT and PD-1 impair tumor antigen\u2013specific CD8 + T cells in melanoma patients. J Clin Investig. 2015;125(5):2046\u201358.","journal-title":"J Clin Investig"},{"issue":"8004","key":"2786_CR135","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/s41586-024-07121-9","volume":"627","author":"X Guan","year":"2024","unstructured":"Guan X, et al. Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells. Nature. 2024;627(8004):646\u201355.","journal-title":"Nature"},{"issue":"3","key":"2786_CR136","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.immuni.2022.02.005","volume":"55","author":"KL Banta","year":"2022","unstructured":"Banta KL, et al. Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8\u2009<\u2009sup>+\u2009T\u00a0cell responses. Immunity. 2022;55(3):512\u2013e5269.","journal-title":"Immunity"},{"issue":"12","key":"2786_CR137","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1158\/0008-5472.CAN-23-2455","volume":"84","author":"D Piovesan","year":"2024","unstructured":"Piovesan D, et al. Fc-Silent Anti-TIGIT Antibodies Potentiate Antitumor Immunity without Depleting Regulatory T Cells. Cancer Res. 2024;84(12):1978\u201395.","journal-title":"Cancer Res"},{"issue":"6","key":"2786_CR138","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","volume":"162","author":"C-H Chang","year":"2015","unstructured":"Chang C-H, et al. Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell. 2015;162(6):1229\u201341.","journal-title":"Cell"},{"issue":"6","key":"2786_CR139","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.cmet.2016.12.018","volume":"25","author":"A Angelin","year":"2017","unstructured":"Angelin A, et al. Foxp3 Reprograms T Cell Metabolism to Function in Low-Glucose, High-Lactate Environments. Cell Metabol. 2017;25(6):1282\u201393. .e7.","journal-title":"Cell Metabol"},{"issue":"2","key":"2786_CR140","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.ccell.2022.01.001","volume":"40","author":"S Kumagai","year":"2022","unstructured":"Kumagai S, et al. Lactic acid promotes PD-1 expression in regulatory T\u00a0cells in highly glycolytic tumor microenvironments. Cancer Cell. 2022;40(2):201\u2013e2189.","journal-title":"Cancer Cell"},{"issue":"7368","key":"2786_CR141","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nature10491","volume":"478","author":"CA Opitz","year":"2011","unstructured":"Opitz CA, et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature. 2011;478(7368):197\u2013203.","journal-title":"Nature"},{"issue":"17","key":"2786_CR142","doi-asserted-by":"publisher","first-page":"3520","DOI":"10.1182\/blood-2009-09-246124","volume":"115","author":"X Liu","year":"2010","unstructured":"Liu X, et al. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood. 2010;115(17):3520\u201330.","journal-title":"Blood"},{"issue":"3","key":"2786_CR143","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.ccell.2018.02.005","volume":"33","author":"Y Liu","year":"2018","unstructured":"Liu Y, et al. Tumor-Repopulating Cells Induce PD-1 Expression in CD8 < sup>+ T Cells by Transferring Kynurenine and AhR Activation. Cancer Cell. 2018;33(3):480\u2013e4947.","journal-title":"Cancer Cell"},{"issue":"32","key":"2786_CR144","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.1200\/JCO.2018.78.9602","volume":"36","author":"TC Mitchell","year":"2018","unstructured":"Mitchell TC, et al. Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I\/II Trial (ECHO-202\/KEYNOTE-037). J Clin Oncol. 2018;36(32):3223\u201330.","journal-title":"J Clin Oncol"},{"issue":"13","key":"2786_CR145","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.1158\/1078-0432.CCR-16-2272","volume":"23","author":"GL Beatty","year":"2017","unstructured":"Beatty GL, et al. First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies. Clin Cancer Res. 2017;23(13):3269\u201376.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2786_CR146","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1158\/0008-5472.CAN-09-3109","volume":"70","author":"D Jin","year":"2010","unstructured":"Jin D, et al. CD73 on Tumor Cells Impairs Antitumor T-Cell Responses: A Novel Mechanism of Tumor-Induced Immune Suppression. Cancer Res. 2010;70(6):2245\u201355.","journal-title":"Cancer Res"},{"issue":"35","key":"2786_CR147","doi-asserted-by":"publisher","first-page":"13132","DOI":"10.1073\/pnas.0605251103","volume":"103","author":"A Ohta","year":"2006","unstructured":"Ohta A, et al. A2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci. 2006;103(35):13132\u20137.","journal-title":"Proc Natl Acad Sci"},{"issue":"5","key":"2786_CR148","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.cmet.2021.02.015","volume":"33","author":"X Ma","year":"2021","unstructured":"Ma X, et al. CD36-mediated ferroptosis dampens intratumoral CD8\u2009<\u2009sup>+\u2009T\u00a0cell effector function and impairs their antitumor ability. Cell Metabol. 2021;33(5):1001\u2013e10125.","journal-title":"Cell Metabol"},{"issue":"2","key":"2786_CR149","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41590-020-00834-9","volume":"22","author":"NE Scharping","year":"2021","unstructured":"Scharping NE, et al. Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion. Nat Immunol. 2021;22(2):205\u201315.","journal-title":"Nat Immunol"},{"issue":"1","key":"2786_CR150","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.cmet.2019.04.002","volume":"30","author":"X Ma","year":"2019","unstructured":"Ma X, et al. Cholesterol Induces CD8 < sup>+ T Cell Exhaustion in the Tumor Microenvironment. Cell Metabol. 2019;30(1):143\u2013e1565.","journal-title":"Cell Metabol"},{"issue":"7858","key":"2786_CR151","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41586-021-03442-1","volume":"593","author":"BI Reinfeld","year":"2021","unstructured":"Reinfeld BI, et al. Cell-programmed nutrient partitioning in the tumour microenvironment. Nature. 2021;593(7858):282\u20138.","journal-title":"Nature"},{"issue":"10","key":"2786_CR152","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1084\/jem.20101159","volume":"208","author":"MB Fuertes","year":"2011","unstructured":"Fuertes MB, et al. Host type I IFN signals are required for antitumor CD8\u2009+\u2009T cell responses through CD8\u03b1\u2009+\u2009dendritic cells. J Exp Med. 2011;208(10):2005\u201316.","journal-title":"J Exp Med"},{"issue":"2","key":"2786_CR153","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1158\/2159-8290.CD-16-1223","volume":"7","author":"DS Shin","year":"2017","unstructured":"Shin DS, et al. Primary Resistance to PD-1 Blockade Mediated by JAK1\/2 Mutations. Cancer Discov. 2017;7(2):188\u2013201.","journal-title":"Cancer Discov"},{"issue":"4","key":"2786_CR154","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.cell.2019.07.019","volume":"178","author":"JL Benci","year":"2019","unstructured":"Benci JL, et al. Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade. Cell. 2019;178(4):933\u2013e94814.","journal-title":"Cell"},{"issue":"7","key":"2786_CR155","doi-asserted-by":"publisher","first-page":"111647","DOI":"10.1016\/j.celrep.2022.111647","volume":"41","author":"W Chen","year":"2022","unstructured":"Chen W, et al. Chronic type I interferon signaling promotes lipid-peroxidation-driven terminal CD8(+) T cell exhaustion and curtails anti-PD-1 efficacy. Cell Rep. 2022;41(7):111647.","journal-title":"Cell Rep"},{"issue":"8","key":"2786_CR156","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1038\/s41590-025-02219-2","volume":"26","author":"SKM Wijesinghe","year":"2025","unstructured":"Wijesinghe SKM, et al. Lymph-node-derived stem-like but not tumor-tissue-resident CD8 + T cells fuel anticancer immunity. Nat Immunol. 2025;26(8):1367\u201383.","journal-title":"Nat Immunol"},{"issue":"3","key":"2786_CR157","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/s41590-026-02419-4","volume":"27","author":"J Lai","year":"2026","unstructured":"Lai J, et al. Flt3L-mediated tumor cDC1 expansion enhances immunotherapy by priming stem-like CD8 + T cells in lymph nodes. Nat Immunol. 2026;27(3):530\u201342.","journal-title":"Nat Immunol"},{"issue":"1","key":"2786_CR158","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.immuni.2022.12.002","volume":"56","author":"N Prokhnevska","year":"2023","unstructured":"Prokhnevska N, et al. CD8\u2009<\u2009sup>+\u2009T\u00a0cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor. Immunity. 2023;56(1):107\u2013e1245.","journal-title":"Immunity"},{"key":"2786_CR159","doi-asserted-by":"crossref","unstructured":"Li Z et al. In vivo labeling reveals continuous trafficking of TCF-1 + T cells between tumor and lymphoid tissue. J Exp Med, 2022; 219(6).","DOI":"10.1084\/jem.20210749"},{"issue":"1","key":"2786_CR160","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ccell.2025.12.004","volume":"44","author":"G Wang","year":"2026","unstructured":"Wang G, et al. Antigen-specific profiling identifies T-bet+ melanoma-specific CD8 + T cells associated with response to neoadjuvant PD-1 blockade. Cancer Cell. 2026;44(1):221\u2013e2345.","journal-title":"Cancer Cell"},{"issue":"2","key":"2786_CR161","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.ccell.2016.06.003","volume":"30","author":"EW Roberts","year":"2016","unstructured":"Roberts EW, et al. Critical Role for CD103 < sup>+\/CD141 < sup>+ Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma. Cancer Cell. 2016;30(2):324\u201336.","journal-title":"Cancer Cell"},{"issue":"1","key":"2786_CR162","doi-asserted-by":"publisher","first-page":"7015","DOI":"10.1038\/s41467-022-34676-w","volume":"13","author":"LB Darragh","year":"2022","unstructured":"Darragh LB, et al. Elective nodal irradiation mitigates local and systemic immunity generated by combination radiation and immunotherapy in head and neck tumors. Nat Commun. 2022;13(1):7015.","journal-title":"Nat Commun"},{"issue":"1","key":"2786_CR163","doi-asserted-by":"publisher","first-page":"5500","DOI":"10.1038\/s41467-024-49873-y","volume":"15","author":"I Telarovic","year":"2024","unstructured":"Telarovic I, et al. Delayed tumor-draining lymph node irradiation preserves the efficacy of combined radiotherapy and immune checkpoint blockade in models of metastatic disease. Nat Commun. 2024;15(1):5500.","journal-title":"Nat Commun"},{"issue":"2","key":"2786_CR164","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41591-023-02760-3","volume":"30","author":"S Pant","year":"2024","unstructured":"Pant S, et al. Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial. Nat Med. 2024;30(2):531\u201342.","journal-title":"Nat Med"},{"issue":"563","key":"2786_CR165","doi-asserted-by":"publisher","first-page":"eaay3575","DOI":"10.1126\/scitranslmed.aay3575","volume":"12","author":"DM Francis","year":"2020","unstructured":"Francis DM, et al. Blockade of immune checkpoints in lymph nodes through locoregional delivery augments cancer immunotherapy. Sci Transl Med. 2020;12(563):eaay3575.","journal-title":"Sci Transl Med"},{"issue":"7749","key":"2786_CR166","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41586-019-1032-7","volume":"567","author":"R Rosenthal","year":"2019","unstructured":"Rosenthal R, et al. Neoantigen-directed immune escape in lung cancer evolution. Nature. 2019;567(7749):479\u201385.","journal-title":"Nature"},{"issue":"7669","key":"2786_CR167","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/nature23477","volume":"548","author":"SJ Patel","year":"2017","unstructured":"Patel SJ, et al. Identification of essential genes for cancer immunotherapy. Nature. 2017;548(7669):537\u201342.","journal-title":"Nature"},{"issue":"4","key":"2786_CR168","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.ccell.2019.08.008","volume":"36","author":"ML Burr","year":"2019","unstructured":"Burr ML, et al. An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer. Cancer Cell. 2019;36(4):385\u2013e4018.","journal-title":"Cancer Cell"},{"issue":"5","key":"2786_CR169","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1084\/jem.20052494","volume":"203","author":"EA Reits","year":"2006","unstructured":"Reits EA, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med. 2006;203(5):1259\u201371.","journal-title":"J Exp Med"},{"issue":"6","key":"2786_CR170","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.cell.2017.10.022","volume":"171","author":"MJ Topper","year":"2017","unstructured":"Topper MJ, et al. Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer. Cell. 2017;171(6):1284\u2013e130021.","journal-title":"Cell"},{"issue":"8","key":"2786_CR171","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1158\/2159-8290.CD-19-1409","volume":"10","author":"DY Torrejon","year":"2020","unstructured":"Torrejon DY, et al. Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade. Cancer Discov. 2020;10(8):1140\u201357.","journal-title":"Cancer Discov"},{"issue":"7916","key":"2786_CR172","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1038\/s41586-022-04772-4","volume":"606","author":"S Badrinath","year":"2022","unstructured":"Badrinath S, et al. A vaccine targeting resistant tumours by dual T cell plus NK cell attack. Nature. 2022;606(7916):992\u20138.","journal-title":"Nature"},{"issue":"9","key":"2786_CR173","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian H, et al. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. N Engl J Med. 2017;376(9):836\u201347.","journal-title":"N Engl J Med"},{"issue":"16","key":"2786_CR174","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, et al. Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia. N Engl J Med. 2014;371(16):1507\u201317.","journal-title":"N Engl J Med"},{"issue":"7","key":"2786_CR175","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.cell.2018.10.014","volume":"175","author":"P Andr\u00e9","year":"2018","unstructured":"Andr\u00e9 P, et al. Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells. Cell. 2018;175(7):1731\u2013e174313.","journal-title":"Cell"},{"issue":"10","key":"2786_CR176","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.1158\/1078-0432.CCR-18-1942","volume":"25","author":"JJ Luke","year":"2019","unstructured":"Luke JJ, et al. WNT\/\u03b2-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers. Clin Cancer Res. 2019;25(10):3074\u201383.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2786_CR177","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/s41467-021-27833-0","volume":"13","author":"Z Qi","year":"2022","unstructured":"Qi Z, et al. Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-PI3K\u03b1\/\u03b2\/\u03b4 treatment. Nat Commun. 2022;13(1):182.","journal-title":"Nat Commun"},{"issue":"3","key":"2786_CR178","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.annonc.2022.12.002","volume":"34","author":"S Scalera","year":"2023","unstructured":"Scalera S, et al. Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma. Ann Oncol. 2023;34(3):275\u201388.","journal-title":"Ann Oncol"},{"issue":"10","key":"2786_CR179","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1038\/nm1096-1096","volume":"2","author":"DI Gabrilovich","year":"1996","unstructured":"Gabrilovich DI, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med. 1996;2(10):1096\u2013103.","journal-title":"Nat Med"},{"issue":"6","key":"2786_CR180","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/nm.3541","volume":"20","author":"GT Motz","year":"2014","unstructured":"Motz GT, et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med. 2014;20(6):607\u201315.","journal-title":"Nat Med"},{"issue":"12","key":"2786_CR181","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","volume":"380","author":"BI Rini","year":"2019","unstructured":"Rini BI, et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019;380(12):1116\u201327.","journal-title":"N Engl J Med"},{"issue":"20","key":"2786_CR182","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020;382(20):1894\u2013905.","journal-title":"N Engl J Med"},{"issue":"1","key":"2786_CR183","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41467-022-35710-7","volume":"14","author":"W Lin","year":"2023","unstructured":"Lin W, et al. Tumor-intrinsic YTHDF1 drives immune evasion and resistance to immune checkpoint inhibitors via promoting MHC-I degradation. Nat Commun. 2023;14(1):265.","journal-title":"Nat Commun"},{"issue":"33","key":"2786_CR184","doi-asserted-by":"publisher","first-page":"20159","DOI":"10.1073\/pnas.1918986117","volume":"117","author":"N Li","year":"2020","unstructured":"Li N, et al. ALKBH5 regulates anti\u2013PD-1 therapy response by modulating lactate and suppressive immune cell accumulation in tumor microenvironment. Proc Natl Acad Sci. 2020;117(33):20159\u201370.","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"2786_CR185","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.cell.2017.06.007","volume":"170","author":"HE Ghoneim","year":"2017","unstructured":"Ghoneim HE, et al. De Novo Epigenetic Programs Inhibit PD-1 Blockade-Mediated T Cell Rejuvenation. Cell. 2017;170(1):142\u2013e15719.","journal-title":"Cell"},{"issue":"2","key":"2786_CR186","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.immuni.2015.01.007","volume":"42","author":"M DuPage","year":"2015","unstructured":"DuPage M, et al. The Chromatin-Modifying Enzyme Ezh2 Is Critical for the Maintenance of Regulatory T Cell Identity after Activation. Immunity. 2015;42(2):227\u201338.","journal-title":"Immunity"},{"key":"2786_CR187","doi-asserted-by":"crossref","unstructured":"Kim YJ et al. Melanoma dedifferentiation induced by IFN-\u03b3 epigenetic remodeling in response to anti\u2013PD-1 therapy. J Clin Investig, 2021; 131(12).","DOI":"10.1172\/JCI145859"},{"issue":"1","key":"2786_CR188","doi-asserted-by":"publisher","first-page":"3946","DOI":"10.1038\/s41467-020-17739-8","volume":"11","author":"J Boshuizen","year":"2020","unstructured":"Boshuizen J, et al. Reversal of pre-existing NGFR-driven tumor and immune therapy resistance. Nat Commun. 2020;11(1):3946.","journal-title":"Nat Commun"},{"issue":"1","key":"2786_CR189","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1038\/s41467-024-46048-7","volume":"15","author":"I-K Kim","year":"2024","unstructured":"Kim I-K, et al. Plasticity-induced repression of Irf6 underlies acquired resistance to cancer immunotherapy in pancreatic ductal adenocarcinoma. Nat Commun. 2024;15(1):1532.","journal-title":"Nat Commun"},{"issue":"1","key":"2786_CR190","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1038\/s41467-018-05992-x","volume":"9","author":"L Wang","year":"2018","unstructured":"Wang L, et al. EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer. Nat Commun. 2018;9(1):3503.","journal-title":"Nat Commun"},{"issue":"1","key":"2786_CR191","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","volume":"165","author":"W Hugo","year":"2016","unstructured":"Hugo W, et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell. 2016;165(1):35\u201344.","journal-title":"Cell"},{"issue":"3","key":"2786_CR192","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.cell.2019.06.014","volume":"178","author":"DW Vredevoogd","year":"2019","unstructured":"Vredevoogd DW, et al. Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold. Cell. 2019;178(3):585\u2013e59915.","journal-title":"Cell"},{"issue":"7827","key":"2786_CR193","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/s41586-020-2746-2","volume":"586","author":"KA Lawson","year":"2020","unstructured":"Lawson KA, et al. Functional genomic landscape of cancer-intrinsic evasion of killing by T cells. Nature. 2020;586(7827):120\u20136.","journal-title":"Nature"},{"issue":"10","key":"2786_CR194","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1113205","volume":"366","author":"M Gerlinger","year":"2012","unstructured":"Gerlinger M, et al. Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing. N Engl J Med. 2012;366(10):883\u201392.","journal-title":"N Engl J Med"},{"issue":"3","key":"2786_CR195","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1172\/JCI45817","volume":"122","author":"H Salmon","year":"2012","unstructured":"Salmon H, et al. Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors. J Clin Investig. 2012;122(3):899\u2013910.","journal-title":"J Clin Investig"},{"issue":"1","key":"2786_CR196","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1136\/gutjnl-2012-302529","volume":"62","author":"MA Jacobetz","year":"2013","unstructured":"Jacobetz MA, et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut. 2013;62(1):112\u201320.","journal-title":"Gut"},{"issue":"3","key":"2786_CR197","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.ccr.2012.01.007","volume":"21","author":"PP Provenzano","year":"2012","unstructured":"Provenzano PP, et al. Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal Adenocarcinoma. Cancer Cell. 2012;21(3):418\u201329.","journal-title":"Cancer Cell"},{"issue":"6","key":"2786_CR198","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.ccr.2014.04.005","volume":"25","author":"BC \u00d6zdemir","year":"2014","unstructured":"\u00d6zdemir BC, et al. Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival. Cancer Cell. 2014;25(6):719\u201334.","journal-title":"Cancer Cell"},{"issue":"27","key":"2786_CR199","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.1200\/JCO.20.00590","volume":"38","author":"EV Cutsem","year":"2020","unstructured":"Cutsem EV, et al. Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma. J Clin Oncol. 2020;38(27):3185\u201394.","journal-title":"J Clin Oncol"},{"issue":"12","key":"2786_CR200","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.jtho.2023.08.018","volume":"18","author":"BC Cho","year":"2023","unstructured":"Cho BC, et al. Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1\u2013High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial. J Thorac Oncol. 2023;18(12):1731\u201342.","journal-title":"J Thorac Oncol"},{"issue":"9","key":"2786_CR201","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1158\/2159-8290.CD-19-1384","volume":"10","author":"Y Kieffer","year":"2020","unstructured":"Kieffer Y, et al. Single-Cell Analysis Reveals Fibroblast Clusters Linked to Immunotherapy Resistance in Cancer. Cancer Discov. 2020;10(9):1330\u201351.","journal-title":"Cancer Discov"},{"issue":"8","key":"2786_CR202","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1158\/2159-8290.CD-19-0094","volume":"9","author":"E Elyada","year":"2019","unstructured":"Elyada E, et al. Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts. Cancer Discov. 2019;9(8):1102\u201323.","journal-title":"Cancer Discov"},{"issue":"2","key":"2786_CR203","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1158\/2159-8290.CD-19-0644","volume":"10","author":"CX Dominguez","year":"2020","unstructured":"Dominguez CX, et al. Single-Cell RNA Sequencing Reveals Stromal Evolution into LRRC15 + Myofibroblasts as a Determinant of Patient Response to Cancer Immunotherapy. Cancer Discov. 2020;10(2):232\u201353.","journal-title":"Cancer Discov"},{"issue":"6657","key":"2786_CR204","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1126\/science.ade2292","volume":"381","author":"R Bill","year":"2023","unstructured":"Bill R, et al. CXCL9:SPP1 macrophage polarity identifies a network of cellular programs that control human cancers. Science. 2023;381(6657):515\u201324.","journal-title":"Science"},{"issue":"3","key":"2786_CR205","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.cell.2021.01.010","volume":"184","author":"S Cheng","year":"2021","unstructured":"Cheng S, et al. A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells. Cell. 2021;184(3):792\u2013e80923.","journal-title":"Cell"},{"issue":"15","key":"2786_CR206","doi-asserted-by":"publisher","first-page":"3998","DOI":"10.1016\/j.cell.2021.05.027","volume":"184","author":"F Marangoni","year":"2021","unstructured":"Marangoni F, et al. Expansion of tumor-associated Treg cells upon disruption of a CTLA-4-dependent feedback loop. Cell. 2021;184(15):3998\u2013e401519.","journal-title":"Cell"},{"issue":"29","key":"2786_CR207","doi-asserted-by":"publisher","first-page":"10113","DOI":"10.1073\/pnas.0711106105","volume":"105","author":"Y Onishi","year":"2008","unstructured":"Onishi Y, et al. Foxp3\u2009<\u2009sup>+ natural regulatory T cells preferentially form aggregates on dendritic cells\u2009<\u2009i\u2009>\u2009in vitro\u2009and actively inhibit their maturation. Proc Natl Acad Sci. 2008;105(29):10113\u20138.","journal-title":"Proc Natl Acad Sci"},{"issue":"7754","key":"2786_CR208","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41586-019-1118-2","volume":"569","author":"F Veglia","year":"2019","unstructured":"Veglia F, et al. Fatty acid transport protein 2 reprograms neutrophils in cancer. Nature. 2019;569(7754):73\u20138.","journal-title":"Nature"},{"issue":"5","key":"2786_CR209","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1084\/jem.20131916","volume":"211","author":"MZ Noman","year":"2014","unstructured":"Noman MZ, et al. PD-L1 is a novel direct target of HIF-1\u03b1, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med. 2014;211(5):781\u201390.","journal-title":"J Exp Med"},{"issue":"10","key":"2786_CR210","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/nm.3337","volume":"19","author":"SM Pyonteck","year":"2013","unstructured":"Pyonteck SM, et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med. 2013;19(10):1264\u201372.","journal-title":"Nat Med"},{"issue":"2","key":"2786_CR211","doi-asserted-by":"publisher","first-page":"e001006","DOI":"10.1136\/jitc-2020-001006","volume":"8","author":"ARA Razak","year":"2020","unstructured":"Razak ARA, et al. Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors. J Immunother Cancer. 2020;8(2):e001006.","journal-title":"J Immunother Cancer"},{"issue":"5","key":"2786_CR212","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.ccell.2017.10.005","volume":"32","author":"V Kumar","year":"2017","unstructured":"Kumar V, et al. Cancer-Associated Fibroblasts Neutralize the Anti-tumor Effect of CSF1 Receptor Blockade by Inducing PMN-MDSC Infiltration of Tumors. Cancer Cell. 2017;32(5):654\u2013e6685.","journal-title":"Cancer Cell"},{"issue":"12","key":"2786_CR213","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1158\/2159-8290.CD-21-0425","volume":"11","author":"A Ribas","year":"2021","unstructured":"Ribas A, et al. Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma. Cancer Discov. 2021;11(12):2998\u20133007.","journal-title":"Cancer Discov"},{"issue":"12","key":"2786_CR214","doi-asserted-by":"publisher","first-page":"5647","DOI":"10.1172\/JCI97570","volume":"128","author":"H-M Chen","year":"2018","unstructured":"Chen H-M, et al. Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunity. J Clin Investig. 2018;128(12):5647\u201362.","journal-title":"J Clin Investig"},{"issue":"16","key":"2786_CR215","doi-asserted-by":"publisher","first-page":"4574","DOI":"10.1158\/1078-0432.CCR-21-1047","volume":"27","author":"KT Byrne","year":"2021","unstructured":"Byrne KT, et al. Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer. Clin Cancer Res. 2021;27(16):4574\u201386.","journal-title":"Clin Cancer Res"},{"issue":"17","key":"2786_CR216","doi-asserted-by":"publisher","first-page":"E4041","DOI":"10.1073\/pnas.1720948115","volume":"115","author":"E Peranzoni","year":"2018","unstructured":"Peranzoni E, et al. Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti\u2013PD-1 treatment. Proc Natl Acad Sci. 2018;115(17):E4041\u201350.","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"2786_CR217","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41591-020-1131-x","volume":"27","author":"J Yu","year":"2021","unstructured":"Yu J, et al. Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination. Nat Med. 2021;27(1):152\u201364.","journal-title":"Nat Med"},{"issue":"52","key":"2786_CR218","doi-asserted-by":"publisher","first-page":"eaba0759","DOI":"10.1126\/sciimmunol.aba0759","volume":"5","author":"JC Lee","year":"2020","unstructured":"Lee JC, et al. Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis. Sci Immunol. 2020;5(52):eaba0759.","journal-title":"Sci Immunol"},{"issue":"5","key":"2786_CR219","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1158\/2326-6066.CIR-16-0325","volume":"5","author":"PC Tumeh","year":"2017","unstructured":"Tumeh PC, et al. Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC. Cancer Immunol Res. 2017;5(5):417\u201324.","journal-title":"Cancer Immunol Res"},{"issue":"6371","key":"2786_CR220","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","volume":"359","author":"B Routy","year":"2018","unstructured":"Routy B, et al. Gut microbiome influences efficacy of PD-1\u2013based immunotherapy against epithelial tumors. Science. 2018;359(6371):91\u20137.","journal-title":"Science"},{"issue":"6371","key":"2786_CR221","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","volume":"359","author":"V Gopalakrishnan","year":"2018","unstructured":"Gopalakrishnan V, et al. Gut microbiome modulates response to anti\u2013PD-1 immunotherapy in melanoma patients. Science. 2018;359(6371):97\u2013103.","journal-title":"Science"},{"issue":"6529","key":"2786_CR222","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1126\/science.abf3363","volume":"371","author":"D Davar","year":"2021","unstructured":"Davar D, et al. Fecal microbiota transplant overcomes resistance to anti\u2013PD-1 therapy in melanoma patients. Science. 2021;371(6529):595\u2013602.","journal-title":"Science"},{"issue":"6529","key":"2786_CR223","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1126\/science.abb5920","volume":"371","author":"EN Baruch","year":"2021","unstructured":"Baruch EN, et al. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science. 2021;371(6529):602\u20139.","journal-title":"Science"},{"issue":"3","key":"2786_CR224","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/s41591-022-01698-2","volume":"28","author":"JA McCulloch","year":"2022","unstructured":"McCulloch JA, et al. Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1. Nat Med. 2022;28(3):545\u201356.","journal-title":"Nat Med"},{"issue":"6575","key":"2786_CR225","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1126\/science.aaz7015","volume":"374","author":"CN Spencer","year":"2021","unstructured":"Spencer CN, et al. Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science. 2021;374(6575):1632\u201340.","journal-title":"Science"},{"issue":"4","key":"2786_CR226","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1038\/s41591-025-04186-5","volume":"32","author":"S Duttagupta","year":"2026","unstructured":"Duttagupta S, et al. Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial. Nat Med. 2026;32(4):1337\u201350.","journal-title":"Nat Med"},{"issue":"8","key":"2786_CR227","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1038\/s41591-023-02453-x","volume":"29","author":"B Routy","year":"2023","unstructured":"Routy B, et al. Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial. Nat Med. 2023;29(8):2121\u201332.","journal-title":"Nat Med"},{"issue":"7982","key":"2786_CR228","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/s41586-023-06568-6","volume":"622","author":"A-M Globig","year":"2023","unstructured":"Globig A-M, et al. The \u03b21-adrenergic receptor links sympathetic nerves to T cell exhaustion. Nature. 2023;622(7982):383\u201392.","journal-title":"Nature"},{"issue":"1","key":"2786_CR229","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41591-018-0221-5","volume":"25","author":"Z Wang","year":"2019","unstructured":"Wang Z, et al. Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade. Nat Med. 2019;25(1):141\u201351.","journal-title":"Nat Med"},{"key":"2786_CR230","doi-asserted-by":"crossref","unstructured":"Fletcher K et al. Immune checkpoint inhibitor infusion times and clinical outcomes in patients with melanoma. Oncologist, 2025; 30(1).","DOI":"10.1093\/oncolo\/oyae197"},{"issue":"21","key":"2786_CR231","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","volume":"372","author":"MA Postow","year":"2015","unstructured":"Postow MA, et al. Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma. N Engl J Med. 2015;372(21):2006\u201317.","journal-title":"N Engl J Med"},{"issue":"1","key":"2786_CR232","doi-asserted-by":"publisher","first-page":"15618","DOI":"10.1038\/ncomms15618","volume":"8","author":"C Vanpouille-Box","year":"2017","unstructured":"Vanpouille-Box C, et al. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat Commun. 2017;8(1):15618.","journal-title":"Nat Commun"},{"issue":"2","key":"2786_CR233","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.immuni.2015.11.024","volume":"44","author":"C Pfirschke","year":"2016","unstructured":"Pfirschke C, et al. Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy. Immunity. 2016;44(2):343\u201354.","journal-title":"Immunity"},{"issue":"26","key":"2786_CR234","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017;377(26):2531\u201344.","journal-title":"N Engl J Med"},{"issue":"23","key":"2786_CR235","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa2210233","volume":"387","author":"MW Rohaan","year":"2022","unstructured":"Rohaan MW, et al. Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma. N Engl J Med. 2022;387(23):2113\u201325.","journal-title":"N Engl J Med"},{"issue":"24","key":"2786_CR236","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1200\/JCO.21.00612","volume":"39","author":"AA Sarnaik","year":"2021","unstructured":"Sarnaik AA, et al. Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma. J Clin Oncol. 2021;39(24):2656\u201366.","journal-title":"J Clin Oncol"},{"issue":"7963","key":"2786_CR237","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas LA, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 2023;618(7963):144\u201350.","journal-title":"Nature"},{"issue":"8054","key":"2786_CR238","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41586-024-08507-5","volume":"639","author":"DA Braun","year":"2025","unstructured":"Braun DA, et al. A neoantigen vaccine generates antitumour immunity in renal cell carcinoma. Nature. 2025;639(8054):474\u201382.","journal-title":"Nature"},{"issue":"17","key":"2786_CR239","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1200\/JCO.2017.73.7379","volume":"36","author":"J Chesney","year":"2018","unstructured":"Chesney J, et al. Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma. J Clin Oncol. 2018;36(17):1658\u201367.","journal-title":"J Clin Oncol"},{"issue":"6","key":"2786_CR240","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","volume":"170","author":"A Ribas","year":"2017","unstructured":"Ribas A, et al. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. Cell. 2017;170(6):1109\u2013e111910.","journal-title":"Cell"},{"issue":"18","key":"2786_CR241","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1056\/NEJMoa2402604","volume":"391","author":"CU Blank","year":"2024","unstructured":"Blank CU, et al. Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma. N Engl J Med. 2024;391(18):1696\u2013708.","journal-title":"N Engl J Med"},{"issue":"9","key":"2786_CR242","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1056\/NEJMoa2211437","volume":"388","author":"SP Patel","year":"2023","unstructured":"Patel SP, et al. Neoadjuvant\u2013Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. N Engl J Med. 2023;388(9):813\u201323.","journal-title":"N Engl J Med"},{"issue":"7","key":"2786_CR243","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/S1470-2045(19)30151-2","volume":"20","author":"EA Rozeman","year":"2019","unstructured":"Rozeman EA, et al. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. Lancet Oncol. 2019;20(7):948\u201360.","journal-title":"Lancet Oncol"},{"issue":"11","key":"2786_CR244","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1200\/JCO.18.01998","volume":"37","author":"C Lebb\u00e9","year":"2019","unstructured":"Lebb\u00e9 C, et al. Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb\/IV CheckMate 511 Trial. J Clin Oncol. 2019;37(11):867\u201375.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2786_CR245","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/nm.4466","volume":"24","author":"C Krieg","year":"2018","unstructured":"Krieg C, et al. High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy. Nat Med. 2018;24(2):144\u201353.","journal-title":"Nat Med"},{"issue":"2","key":"2786_CR246","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41591-021-01623-z","volume":"28","author":"AX Lozano","year":"2022","unstructured":"Lozano AX, et al. T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma. Nat Med. 2022;28(2):353\u201362.","journal-title":"Nat Med"},{"issue":"1","key":"2786_CR247","doi-asserted-by":"publisher","first-page":"4946","DOI":"10.1038\/s41467-020-18742-9","volume":"11","author":"Y Jing","year":"2020","unstructured":"Jing Y, et al. Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy. Nat Commun. 2020;11(1):4946.","journal-title":"Nat Commun"},{"issue":"8","key":"2786_CR248","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1093\/neuonc\/noae085","volume":"26","author":"JD Hendriksen","year":"2024","unstructured":"Hendriksen JD, et al. Immunotherapy drives mesenchymal tumor cell state shift and TME immune response in glioblastoma patients. Neuro Oncol. 2024;26(8):1453\u201366.","journal-title":"Neuro Oncol"},{"issue":"3","key":"2786_CR249","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/S1470-2045(25)00709-0","volume":"27","author":"R Dummer","year":"2026","unstructured":"Dummer R, et al. Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB-IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 study. Lancet Oncol. 2026;27(3):327\u201339.","journal-title":"Lancet Oncol"},{"key":"2786_CR250","doi-asserted-by":"crossref","unstructured":"Fransen MF et al. Tumor-draining lymph nodes are pivotal in PD-1\/PD-L1 checkpoint therapy. JCI Insight, 2018; 3(23).","DOI":"10.1172\/jci.insight.124507"},{"issue":"83","key":"2786_CR251","doi-asserted-by":"publisher","first-page":"eabn6173","DOI":"10.1126\/sciimmunol.abn6173","volume":"8","author":"M van Gulijk","year":"2023","unstructured":"van Gulijk M, et al. PD-L1 checkpoint blockade promotes regulatory T cell activity that underlies therapy resistance. Sci Immunol. 2023;8(83):eabn6173.","journal-title":"Sci Immunol"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02786-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-026-02786-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02786-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T02:02:02Z","timestamp":1789869722000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12943-026-02786-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,20]]},"references-count":251,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2786"],"URL":"https:\/\/doi.org\/10.1186\/s12943-026-02786-4","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,20]]},"assertion":[{"value":"28 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"222"}}